Simon P. Watkins

2.0k total citations
17 papers, 166 citations indexed

About

Simon P. Watkins is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Simon P. Watkins has authored 17 papers receiving a total of 166 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Simon P. Watkins's work include PARP inhibition in cancer therapy (15 papers), Prostate Cancer Treatment and Research (8 papers) and Cancer Genomics and Diagnostics (6 papers). Simon P. Watkins is often cited by papers focused on PARP inhibition in cancer therapy (15 papers), Prostate Cancer Treatment and Research (8 papers) and Cancer Genomics and Diagnostics (6 papers). Simon P. Watkins collaborates with scholars based in United States, United Kingdom and Spain. Simon P. Watkins's co-authors include Jim Xiao, Howard A. Burris, Lara Maloney, Jeff Isaacson, Manish R. Patel, Sarah Jaw‐Tsai, Geoffrey I. Shapiro, Andrew D. Simmons, Yvette Drew and Wassim Abida and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Simon P. Watkins

16 papers receiving 162 citations

Peers

Countries citing papers authored by Simon P. Watkins

Since Specialization

Citations

This map shows the geographic impact of Simon P. Watkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon P. Watkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon P. Watkins more than expected).

Fields of papers citing papers by Simon P. Watkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon P. Watkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon P. Watkins. The network helps show where Simon P. Watkins may publish in the future.

Co-authorship network of co-authors of Simon P. Watkins

This figure shows the co-authorship network connecting the top 25 collaborators of Simon P. Watkins. A scholar is included among the top collaborators of Simon P. Watkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon P. Watkins. Simon P. Watkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Title	Journal	Authors	Indexed citations
1	Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.	Journal of Clinical Oncology	Alan H. Bryce, Josep M. Piulats et al.	10
2	A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration	Current Oncology	Brieuc Sautois, Andrea Loehr et al.	1
3	What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib	Frontiers in Oncology	Daniel P. Petrylak, Simon P. Watkins et al.	0
4	Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.	Journal of Clinical Oncology	Hanna Tukachinsky, Russell W. Madison et al.	2
5	659P Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2	Annals of Oncology	S. Chowdhury, Akash Patnaik et al.	2
6	Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors	Investigational New Drugs	Mingxiang Liao, Simon P. Watkins et al.	29
7	Abstract 727: Comprehensive genomic profiling of >1000 plasma and tumor tissue samples from metastatic castration-resistant prostate cancer (mCRPC) patients gives insight into targeted treatment strategies	Cancer Research	Jeremy Shapiro, Ray McDermott et al.	1
8	Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2.	Journal of Clinical Oncology	Wassim Abida, Alan H. Bryce et al.	4
9	TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).	Journal of Clinical Oncology	Charles J. Ryan, Wassim Abida et al.	22
10	Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors	Clinical Pharmacology in Drug Development	Geoffrey I. Shapiro, Rebecca Kristeleit et al.	31
11	Evaluation of Drug–Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor	Clinical and Translational Science	Jim Xiao, Dorota Nowak et al.	19
12	Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)	Annals of Oncology	S. Chowdhury, Ray McDermott et al.	3
13	The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)	Annals of Oncology	S. Chowdhury, Wassim Abida et al.	2
14	Trial of rucaparib in prostate indications 3 (TRITON3): An international, multicenter, randomized, open-label phase 3 study of rucaparib vs physician’s choice of therapy for patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).	Journal of Clinical Oncology	Charles J. Ryan, Simon P. Watkins et al.	3
15	A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation.	Journal of Clinical Oncology	Ronnie Shapira‐Frommer, Amit M. Oza et al.	15
16	2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation	European Journal of Cancer	Ronnie Shapira‐Frommer, Amit M. Oza et al.	16
17	A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixed-dose capecitabine in metastatic breast cancer (MBC).	Journal of Clinical Oncology	Michelle A. Rudek, Elizabeth Garrett‐Mayer et al.	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact